MMPs 2 and 9 are essential for coronary collateral growth and are prominently regulated by p38 MAPK

Journal of Molecular and Cellular Cardiology

Volumn 51, Issue 6, 2011, Pages 1015-1025

  Dodd, Tracy ^a   Jadhav, Rashmi ^a   Wiggins, Luke ^a   Stewart, James ^b   Smith, Erika ^a   Russell, James C ^c   Rocic, Petra ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Coronary collateral growth; ECM remodeling; MMPs; P38 MAPK; Transient repetitive ischemia

Indexed keywords

COLLAGEN TYPE 4; ELASTIN; GELATINASE A; GELATINASE B; LAMININ; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; CONTROLLED STUDY; CORONARY ARTERY COLLATERAL CIRCULATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING; ZYMOGRAPHY;

ANIMALS; COLLAGEN TYPE IV; COLLATERAL CIRCULATION; CORONARY VESSELS; ELASTIN; ENZYME ACTIVATION; IMIDAZOLES; LAMININ; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MYOCARDIAL ISCHEMIA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

RATTUS;

EID: 80055117228     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.08.012     Document Type: Article

References (79)

1. Chen W., Gabel S., Steenbergen C., Murphy E. A redox-based mechanism for cardioprotection induced by ischemic preconditioning in perfused rat heart. Circ Res 1995, 77:424-429.
2. Seiler C. The human coronary collateral circulation. Heart 2003, 89:1352-1357.
3. Waltenberger J. Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc Res 2001, 49:554-560.
4. Yilmaz M.B., Biyikoglu S.F., Akin Y., Guray U., Kisacik H.L., Korkmaz S. Obesity is associated with impaired coronary collateral vessel development. Int J Obes Relat Metab Disord 2003, 27:1541-1545.
5. Reed R., Kolz C., Potter B., Rocic P. The mechanistic basis for the disparate effects of angiotensin II on coronary collateral growth. Arterioscler Thromb Vasc Biol 2008, 28:61-67.
6. Wilson D., Massaeli H., Russell J.C., Pierce G.N., Zahradka P. Low matrix metalloproteinase levels precede vascular lesion formation in the JCR:LA-cp rat. Mol Cell Biochem 2003, 249:151-155.
7. Scholz D., Cai W.J., Schaper W. Arteriogenesis, a new concept of vascular adaptation in occlusive disease. Angiogenesis 2001, 4:247-257.
8. Unthank J.L., Nixon J.C., Lash J.M. Early adaptations in collateral and microvascular resistances after ligation of the rat femoral artery. J Appl Physiol 1995, 79:73-82.
9. Schaper W. Collateral circulation: past and present. Basic Res Cardiol 2009, 104:5-21.
10. Jones C.B., Sane D.C., Herrington D.M. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003, 59:812-823.
11. Giannelli G., Falk-Marzillier J., Schiraldi O., Stetler-Stevenson W.G., Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997, 277:225-228.
12. Murphy G., Nguyen Q., Cockett M.I., Atkinson S.J., Allan J.A., Knight C.G., et al. Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. J Biol Chem 1994, 269:6632-6636.
13. Nagase H., Woessner J.F. Matrix metalloproteinases. J Biol Chem 1999, 274:21491-21494.
14. Van den Steen P.E., Dubois B., Nelissen I., Rudd P.M., Dwek R.A., Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002, 37:375-536.
15. Zucker S., Pei D., Cao J., Lopez-Otin C. Membrane type-matrix metalloproteinases (MT-MMP). Curr Top Dev Biol 2003, 54:1-74.
16. Overall C.M., Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002, 2:657-672.
17. Cai W.J., Kocsis E., Wu X., Rodriguez M., Luo X., Schaper W., et al. Remodeling of the vascular tunica media is essential for development of collateral vessels in the canine heart. Mol Cell Biochem 2004, 264:201-210.
18. Haas T.L., Doyle J.L., Distasi M.R., Norton L.E., Sheridan K.M., Unthank J.L. Involvement of MMPs in the outward remodeling of collateral mesenteric arteries. Am J Physiol Heart Circ Physiol 2007, 293:H2429-H2437.
19. Vincenti M.P., Brinckerhoff C.E. Signal transduction and cell-type specific regulation of matrix metalloproteinase gene expression: can MMPs be good for you?. J Cell Physiol 2007, 213:355-364.
20. McCawley L.J., Li S., Wattenberg E.V., Hudson L.G. Sustained activation of the mitogen-activated protein kinase pathway. A mechanism underlying receptor tyrosine kinase specificity for matrix metalloproteinase-9 induction and cell migration. J Biol Chem 1999, 274:4347-4353.
21. Eberhardt W., Huwiler A., Beck K.F., Walpen S., Pfeilschifter J. Amplification of IL-1 beta-induced matrix metalloproteinase-9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NF-kappa B and activating protein-1 and involves activation of the mitogen-activated protein kinase pathways. J Immunol 2000, 165:5788-5797.
22. Liang K.C., Lee C.W., Lin W.N., Lin C.C., Wu C.B., Luo S.F., et al. Interleukin-1beta induces MMP-9 expression via p42/p44 MAPK, p38 MAPK, JNK, and nuclear factor-kappaB signaling pathways in human tracheal smooth muscle cells. J Cell Physiol 2007, 211:759-770.
23. Rocic P., Kolz C., Reed R., Potter B., Chilian W.M. Optimal reactive oxygen species concentration and p38 MAP kinase are required for coronary collateral growth. Am J Physiol Heart Circ Physiol 2007, 292:H2729-H2736.
24. Reed R., Potter B., Smith E., Jadhav R., Villalta P., Jo H., et al. Redox-sensitive Akt and Src regulate coronary collateral growth in metabolic syndrome. Am J Physiol Heart Circ Physiol 2009, 296:H1811-H1821.
25. Toyota E., Warltier D.C., Brock T., Ritman E., Kolz C., O'Malley P., et al. Vascular endothelial growth factor is required for coronary collateral growth in the rat. Circulation 2005, 112:2108-2113.
26. Jadhav R., Dodd T., Smith E., Bailey E., Delucia A.L., Russell J.C., et al. Angiotensin type I receptor blockade in conjunction with enhanced Akt activation restores coronary collateral growth in the metabolic syndrome. Am J Physiol Heart Circ Physiol 2011, 300:H1938-H1949.
27. Monaco S., Sparano V., Gioia M., Sbardella D., Di Pierro D., Marini S., et al. Enzymatic processing of collagen IV by MMP-2 (gelatinase A) affects neutrophil migration and it is modulated by extracatalytic domains. Protein Sci 2006, 15:2805-2815.
28. Mainardi C.L., Dixit S.N., Kang A.H. Degradation of type IV (basement membrane) collagen by a proteinase isolated from human polymorphonuclear leukocyte granules. J Biol Chem 1980, 255:5435-5441.
29. Gu Z., Cui J., Brown S., Fridman R., Mobashery S., Strongin A.Y., et al. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci 2005, 25:6401-6408.
30. Ardini E., Sporchia B., Pollegioni L., Modugno M., Ghirelli C., Castiglioni F., et al. Identification of a novel function for 67-kDa laminin receptor: increase in laminin degradation rate and release of motility fragments. Cancer Res 2002, 62:1321-1325.
31. Sivaprasad S., Chong N.V., Bailey T.A. Serum elastin-derived peptides in age-related macular degeneration. Invest Ophthalmol Vis Sci 2005, 46:3046-3051.
32. Lei H., Kalluri R., Furth E.E., Baker A.H., Strauss J.F. Rat amnion type IV collagen composition and metabolism: implications for membrane breakdown. Biol Reprod 1999, 60:176-182.
33. Yao P.L., Lin Y.C., Richburg J.H. TNF alpha-mediated disruption of spermatogenesis in response to Sertoli cell injury in rodents is partially regulated by MMP2. Biol Reprod 2009, 80:581-589.
34. Brown S., Bernardo M.M., Li Z.H., Kotra L.P., Tanaka Y., Fridman R., et al. Potent and selective mechanism-based inhibition of gelatinases. J Am Chem Soc 2000, 122:6799-6800.
35. Qiu L.B., Zhou Y., Wang Q., Yang L.L., Liu H.Q., Xu S.L., et al. Synthetic gelatinases inhibitor attenuates electromagnetic pulse-induced blood-brain barrier disruption by inhibiting gelatinases-mediated ZO-1 degradation in rats. Toxicology 2011, 285:31-38.
36. Cai W.J., Koltai S., Kocsis E., Scholz D., Kostin S., Luo X., et al. Remodeling of the adventitia during coronary arteriogenesis. Am J Physiol Heart Circ Physiol 2003, 284:H31-H40.
37. Cai W., Vosschulte R., Afsah-Hedjri A., Koltai S., Kocsis E., Scholz D., et al. Altered balance between extracellular proteolysis and antiproteolysis is associated with adaptive coronary arteriogenesis. J Mol Cell Cardiol 2000, 32:997-1011.
38. Ries C., Popp T., Egea V., Kehe K., Jochum M. Matrix metalloproteinase-9 expression and release from skin fibroblasts interacting with keratinocytes: upregulation in response to sulphur mustard. Toxicology 2009, 263:26-31.
39. Mias C., Lairez O., Trouche E., Roncalli J., Calise D., Seguelas M.H., et al. Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction. Stem Cells 2009, 27:2734-2743.
40. Kusukawa J., Sasaguri Y., Shima I., Kameyama T., Morimatsu M. Expression of matrix metalloproteinase-2 related to lymph node metastasis of oral squamous cell carcinoma. A clinicopathologic study. Am J Clin Pathol 1993, 99:18-23.
41. Kossakowska A.E., Hinek A., Edwards D.R., Lim M.S., Zhang C.L., Breitman D.R., et al. Proteolytic activity of human non-Hodgkin's lymphomas. Am J Pathol 1998, 152:565-576.
42. Mydel P., Shipley J.M., Adair-Kirk T.L., Kelley D.G., Broekelmann T.J., Mecham R.P., et al. Neutrophil elastase cleaves laminin-332 (laminin-5) generating peptides that are chemotactic for neutrophils. J Biol Chem 2008, 283:9513-9522.
43. Fukuda S., Fini C.A., Mabuchi T., Koziol J.A., Eggleston L.L., del Zoppo G.J. Focal cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke 2004, 35:998-1004.
44. Bond M., Fabunmi R.P., Baker A.H., Newby A.C. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett 1998, 435:29-34.
45. Moon S.K., Cha B.Y., Kim C.H. ERK1/2 mediates TNF-alpha-induced matrix metalloproteinase-9 expression in human vascular smooth muscle cells via the regulation of NF-kappaB and AP-1: involvement of the ras dependent pathway. J Cell Physiol 2004, 198:417-427.
46. Yokoo T., Kitamura M. Dual regulation of IL-1 beta-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-kappa B and AP-1. Am J Physiol 1996, 270:F123-F130.
47. Sariahmetoglu M., Crawford B.D., Leon H., Sawicka J., Li L., Ballermann B.J., et al. Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation. FASEB J 2007, 21:2486-2495.
48. Pap T., Pap G., Hummel K.M., Franz J.K., Jeisy E., Sainsbury I., et al. Membrane-type-1 matrix metalloproteinase is abundantly expressed in fibroblasts and osteoclasts at the bone-implant interface of aseptically loosened joint arthroplasties in situ. J Rheumatol 1999, 26:166-169.
49. Lagente V., Boichot E. Role of matrix metalloproteinases in the inflammatory process of respiratory diseases. J Mol Cell Cardiol 2010, 48:440-444.
50. Kumar B., Koul S., Petersen J., Khandrika L., Hwa J.S., Meacham R.B., et al. p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer Res 2010, 70:832-841.
51. Keshet Y., Seger R. The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods Mol Biol 2010, 661:3-38.
52. Schieven G.L. The biology of p38 kinase: a central role in inflammation. Curr Top Med Chem 2005, 5:921-928.
53. Rousseau S., Houle F., Huot J. Integrating the VEGF signals leading to actin-based motility in vascular endothelial cells. Trends Cardiovasc Med 2000, 10:321-327.
54. Yang S., Xin X., Zlot C., Ingle G., Fuh G., Li B., et al. Vascular endothelial cell growth factor-driven endothelial tube formation is mediated by vascular endothelial cell growth factor receptor-2, a kinase insert domain-containing receptor. Arterioscler Thromb Vasc Biol 2001, 21:1934-1940.
55. Issbrucker K., Marti H.H., Hippenstiel S., Springmann G., Voswinckel R., Gaumann A., et al. p38 MAP kinase-a molecular switch between VEGF-induced angiogenesis and vascular hyperpermeability. FASEB J 2003, 17:262-264.
56. Boyd P.J., Doyle J., Gee E., Pallan S., Haas T.L. MAPK signaling regulates endothelial cell assembly into networks and expression of MT1-MMP and MMP-2. Am J Physiol Cell Physiol 2005, 288:C659-C668.
57. Curry J.M., Eubank T.D., Roberts R.D., Wang Y., Pore N., Maity A., et al. M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. PLoS One 2008, 3:e3405.
58. Whyte J., Bergin O., Bianchi A., McNally S., Martin F. Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Res 2009, 11:209.
59. Swarnakar S., Paul S., Singh L.P., Reiter R.J. Matrix metalloproteinases in health and disease: regulation by melatonin. J Pineal Res 2011, 50:8-20.
60. Touyz R.M. Mitochondrial redox control of matrix metalloproteinase signaling in resistance arteries. Arterioscler Thromb Vasc Biol 2006, 26:685-688.
61. Wei S., Rothstein E.C., Fliegel L., Dell'Italia L.J., Lucchesi P.A. Differential MAP kinase activation and Na(+)/H(+) exchanger phosphorylation by H(2)O(2) in rat cardiac myocytes. Am J Physiol Cell Physiol 2001, 281:C1542-C1550.
62. Taniyama Y., Ushio-Fukai M., Hitomi H., Rocic P., Kingsley M.J., Pfahnl C., et al. Role of p38 MAPK and MAPKAPK-2 in angiotensin II-induced Akt activation in vascular smooth muscle cells. Am J Physiol Cell Physiol 2004, 287:C494-C499.
63. Kandasamy A.D., Chow A.K., Ali M.A., Schulz R. Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res 2010, 85:413-423.
64. Cuenda A., Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007, 1773:1358-1375.
65. Cook R., Wu C.C., Kang Y.J., Han J. The role of the p38 pathway in adaptive immunity. Cell Mol Immunol 2007, 4:253-259.
66. Wu W.S. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev 2006, 25:695-705.
67. Luangdilok S., Box C., Harrington K., Rhys-Evans P., Eccles S. MAPK and PI3K signalling differentially regulate angiogenic and lymphangiogenic cytokine secretion in squamous cell carcinoma of the head and neck. Eur J Cancer 2011, 47:520-529.
68. Spallarossa P., Altieri P., Garibaldi S., Ghigliotti G., Barisione C., Manca V., et al. Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: the role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res 2006, 69:736-745.
69. Meisner J.K., Price R.J. Spatial and temporal coordination of bone marrow-derived cell activity during arteriogenesis: regulation of the endogenous response and therapeutic implications. Microcirculation 2010, 17:583-599.
70. Newby A.C. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 2008, 28:2108-2114.
71. Yun J., Rocic P., Pung Y.F., Belmadani S., Carrao A.C., Ohanyan V., et al. Redox-dependent mechanisms in coronary collateral growth: the "redox window" hypothesis. Antioxid Redox Signal 2009, 11:1961-1974.
72. Kaneko H., Anzai T., Takahashi T., Kohno T., Shimoda M., Sasaki A., et al. Role of vascular endothelial growth factor-A in development of abdominal aortic aneurysm. Cardiovasc Res 2011, 91:358-367.
73. Ghosh S., Maity P. VEGF antibody plus cisplatin reduces angiogenesis and tumor growth in a xenograft model of ovarian cancer. J Environ Pathol Toxicol Oncol 2010, 29:17-30.
74. Funahashi Y., Shawber C.J., Sharma A., Kanamaru E., Choi Y.K., Kitajewski J. Notch modulates VEGF action in endothelial cells by inducing Matrix Metalloprotease activity. Vasc Cell 2011, 3:2-22.
75. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000, 2:737-744.
76. Hiraoka N., Allen E., Apel I.J., Gyetko M.R., Weiss S.J. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998, 95:365-377.
77. Steingen C., Brenig F., Baumgartner L., Schmidt J., Schmidt A., Bloch W. Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells. J Mol Cell Cardiol 2008, 44:1072-1084.
78. Lee S., Jilani S.M., Nikolova G.V., Carpizo D., Iruela-Arispe M.L. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005, 169:681-691.
79. Suhr F., Brixius K., Bloch W. Angiogenic and vascular modulation by extracellular matrix cleavage products. Curr Pharm Des 2009, 15:389-410.